Abstracts tagged "IgG4 Related Disease and Retroperitoneal Fibrosing"

Abstract Number: 1237 • 2014 ACR/ARHP Annual Meeting
Retroperitoneal Fibrosis and IgG4 Disease: Response to Immunosuppressive Therapy – a Single Centre Retrospective Study
Shirish Sangle¹, Pamela Lutalo², Louise Nel³, James Pattison⁴, Tim OBrien⁵ and David P. D'Cruz⁶, ¹Rheumatology, Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ²Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ³Rheumatology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ⁴Nephrology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ⁵Urology, Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ⁶Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: A retrospective observational study of patients with IgG4 related disease and retroperitoneal fibrosis Methods: Retroperitoneal fibrosis (RPF) is a rare chronic inflammatory condition which…
Abstract Number: 2022 • 2013 ACR/ARHP Annual Meeting
The Comparison Between IgG4-Related Retroperitoneal Fibrosis and Idiopathic Retroperitoneal Fibrosis
Bon San Koo¹, Bin Yoo¹, Chang-Keun Lee¹, Yong-Gil Kim¹, You Jae Kim¹, Seokchan Hong², Wook Jang Seo³ and Kyung joo Ahn⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Department of rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Seoul Veterans Hospital, Seoul, South Korea, ⁴KEPCO medical center, Seoul, South Korea
The comparison between IgG4-related retroperitoneal fibrosis and idiopathic retroperitoneal fibrosis Background/Purpose: The purpose of our study was to identify the ratio of IgG4-related retroperitoneal fibrosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].